ReviewDer Pathologe2018
[Updates on tumours of the salivary glands : 2017 WHO classification].
Review in Der Pathologe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- An integrated clinical and imaging-based machine learning model to determine the preoperative nature of primary operable parotid tumors.BMC oral health · 2026Article
- Multispectral optoacoustic tomography of benign parotid tumors in vivo: a prospective observational pilot study.Scientific reports · 2024Observational
- Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers.Cancers · 2024Review
- [Salivary gland carcinomas - Monocentric experience on subtypes and their incidences over 42 years].Laryngo- rhino- otologie · 2023Article
- Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany.Journal of cancer research and clinical oncology · 2023Article
- Prognostic effects of surgery or radiotherapy on adenoid cystic carcinoma of the head and neck: a retrospective cohort study.Gland surgery · 2022Article
- [Myoepithelial carcinoma of the parotid gland: a rare tumor with diagnostic challenges].Wiener medizinische Wochenschrift (1946) · 2022Article
- Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer.Journal of clinical medicine · 2022Review
- Rare Diseases of the Salivary Glands and of Facial Nerve.Laryngo- rhino- otologie · 2021Article
- [Diagnostic and predictive molecular pathology of head and neck neoplasms].Der Pathologe · 2018Review
- Contemporary Management of Benign and Malignant Parotid Tumors.Frontiers in surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the new 2017 WHO classification, a reduction of the high number of entities of salivary carcinomas was implemented. There is only one new carcinoma entity: secretory carcinoma. There is a slight increase of reactive and benign entities by the inclusion of rare and well-established, but so far not included, lesions. Furthermore, there are some conceptual changes and pure changes in terminology. The impact of molecular findings is increasing and is so far restricted to diagnostic aspects.
Indexed as
Identifiers
29372306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.